WHO Approves First Ebola Bundibugyo Diagnostic Amid Escalating Outbreak in DRC

In a pivotal moment for global public health, the World Health Organization (WHO) has granted its Emergency Use Listing (EUL) to the inaugural molecular diagnostic test for the Bundibugyo virus (BDBV), a deadly strain of Ebola. This critical intervention arrives amidst the most extensive recorded outbreak of BDBV, currently ravaging regions of the Democratic Republic of Congo (DRC) and impacting neighboring Uganda, highlighting the urgent need for swift and accurate diagnostic capabilities on the front lines.

Quick summary

• The WHO has issued its first Emergency Use Listing for a diagnostic test specifically targeting the Ebola Bundibugyo virus, capable of rapidly identifying its genetic material in blood samples.
• This crucial listing follows the WHO Director-General's declaration of a Public Health Emergency of International Concern (PHEIC) in May 2026, spurred by the largest recorded outbreak of BDBV in the DRC and Uganda.
• The new diagnostic tool is vital for enhancing early case detection, guiding timely clinical care, improving disease surveillance, and bolstering effective outbreak response efforts, particularly in low- and middle-income countries.
• The approval process was significantly expedited, demonstrating a streamlined approach to deploying quality-assured health products during fast-moving public health crises.

Why it matters

The addition of this BDBV diagnostic test to the WHO's Emergency Use Listing represents a monumental stride in global health security, particularly for regions frequently impacted by viral hemorrhagic fevers. For health workers and public health officials in the DRC and Uganda, this means access to a reliable, quality-assured tool that can confirm infections rapidly, cutting down on the agonizing wait times that can impede effective containment. Early and accurate diagnosis is not merely a clinical convenience; it is a linchpin in breaking chains of transmission, enabling prompt isolation of infected individuals, and initiating life-saving treatment faster.

Beyond the immediate clinical benefits, the EUL significantly impacts national and international procurement efforts. United Nations agencies and governments can now make informed, confident decisions when acquiring these essential products, knowing they meet rigorous international standards for quality, safety, and performance. This accelerated procurement pathway is especially critical in low- and middle-income countries, where access to advanced diagnostic technologies can be limited. Ultimately, this listing helps to level the playing field, ensuring that communities most vulnerable to such outbreaks are equipped with the tools necessary to protect public health and save lives.

Background

The Bundibugyo virus (BDBV) is one of three Ebola virus species known to instigate large, severe, and often fatal outbreaks in humans. Like other filoviruses, it transmits from animals to humans and subsequently spreads through human-to-human contact, primarily via bodily fluids from infected individuals, deceased persons, or contaminated surfaces. The disease it causes, Bundibugyo virus disease, is characterized by severe symptoms and a high fatality rate, demanding swift and decisive public health action.

The urgency for a dedicated diagnostic tool reached a crescendo following the current outbreak. On May 17, 2026, WHO Director-General Dr. Tedros Adhanom Ghebreyesus officially declared a Public Health Emergency of International Concern (PHEIC) due to the expanding BDBV outbreak originating in the Democratic Republic of Congo, with confirmed cases also reported in Uganda. As of the announcement date, the DRC alone had reported a staggering 1,406 laboratory-confirmed cases and 438 deaths, underscoring the severity and widespread nature of the crisis.

Prior to this development, diagnostic capabilities for BDBV were severely constrained. Initial testing capacity was limited to a handful of sites, predominantly the Institut National de Recherche Biomédicale in Kinshasa and Goma, with an estimated combined daily capacity of merely 200–400 tests. This bottleneck significantly hampered rapid case identification and effective surveillance. The declaration of the PHEIC swiftly prompted the WHO to issue a call for manufacturers of in vitro diagnostics (IVDs) for BDBV to submit expressions of interest for EUL consideration, setting the stage for the rapid review and approval of this groundbreaking diagnostic test.

Accelerating Global Health Response: The EUL Mechanism

The WHO's Emergency Use Listing (EUL) procedure is a pivotal mechanism designed to expedite access to critical health products during public health crises. It meticulously assesses the quality, safety, and performance of essential health tools based on available evidence, ensuring they not only meet minimum international standards but are also appropriate for the specific needs of low- and middle-income countries. This streamlined process is a deliberate effort by the WHO to bridge the gap between scientific innovation and urgent public health demand, without compromising on product integrity.

Dr. Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data, emphasized the dual imperative of speed and confidence in emergency response. "Public health emergencies require not only speed, but also confidence that the health products being used meet standards for quality, safety and performance," she stated. "During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission. Through this Emergency Use Listing, WHO is helping countries access trusted diagnostic tools more rapidly so that they can respond more effectively.” Her words underscore the EUL's role in empowering nations to tackle outbreaks with trusted, high-caliber instruments.

The rapidity with which this EUL was granted, less than two weeks after the call for manufacturers, showcases the adaptability and responsiveness of global health regulatory bodies under extreme pressure. This accelerated timeline is a testament to the WHO's commitment to proactive engagement with manufacturers and partners, ensuring that critical diagnostic solutions can reach affected populations precisely when they are needed most.

Expanding Diagnostic Frontiers in Crisis

Even before the EUL of the new molecular test, significant strides had been made in expanding diagnostic capacity for BDBV. With robust support from the WHO and the Africa Centres for Disease Control and Prevention (Africa CDC), the laboratory testing network has dramatically grown. What was once a limited cluster of sites now encompasses a broader network of 10 laboratories across affected provinces, collectively boosting daily testing capacity to over 2,000 tests. This expansion is a testament to the intensified global and regional collaboration aimed at strengthening epidemic preparedness and response.

The introduction of the first EUL-approved molecular diagnostic test will further amplify these efforts. Its rapid and reliable capabilities are indispensable for continuing to identify new cases early, enabling prompt isolation measures, and guiding patient care pathways more effectively. This synergy between expanded infrastructure and advanced diagnostic tools is crucial for interrupting transmission chains and ultimately bringing the current BDBV outbreak under control.

In parallel, the WHO and Africa CDC, alongside partners such as PATH, FIND, CHAI, and with Unitaid's backing, are establishing a joint validation platform. This initiative focuses on the rapid evaluation of a diverse range of diagnostic products, including laboratory-based molecular tests, near-point-of-care molecular tests, and antigen rapid diagnostic tests. This comprehensive approach aims to generate vital clinical evidence on the performance of these products directly within outbreak settings, paving the way for even more versatile and accessible diagnostic solutions in the future.

The Broader Fight Against Viral Hemorrhagic Fevers

The ongoing struggle against the Bundibugyo virus is emblematic of the broader, relentless fight against viral hemorrhagic fevers globally. These diseases, often characterized by their sudden onset, rapid spread, and high mortality rates, pose persistent threats to public health systems, especially in areas with limited resources. The lessons learned and the mechanisms refined in responding to the BDBV outbreak hold significant implications for future epidemics involving other pathogens.

The WHO's continuous engagement with manufacturers, global partners, and national governments underscores a foundational commitment to enhancing the availability and accessibility of safe, effective, and quality-assured life-saving health products worldwide. This collaborative ecosystem is vital for not only containing current outbreaks but also for building resilient health systems capable of anticipating and responding to future threats. By investing in diagnostics, surveillance, and rapid response capabilities, the international community reinforces its collective ability to protect global health security.

Qnews24h insight

The swift approval of the first diagnostic test for Ebola Bundibugyo virus under the WHO's Emergency Use Listing during a major outbreak represents more than just a regulatory milestone; it signals a refined and agile paradigm for global health emergency response. In an era where novel pathogens can emerge and spread with unprecedented speed, the traditional, lengthy regulatory processes for medical devices can be a critical impediment. This rapid EUL demonstrates that international bodies can, and must, streamline these pathways without compromising on rigorous standards for quality, safety, and performance. The insight lies in recognizing this moment as a precedent: a model for how global collaboration, expedited regulatory frameworks, and targeted investment in diagnostic capabilities can work in concert to confront fast-moving public health crises effectively. It highlights an evolving landscape where speed is matched with scientific integrity, ultimately providing frontline responders with the critical tools necessary to save lives and contain outbreaks before they spiral further out of control.

Sources

• WHO adds first diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing - World Health Organization

FAQ

What is the Bundibugyo virus?

The Bundibugyo virus (BDBV) is one of the species of Ebola virus known to cause severe, often life-threatening disease in humans. It can spread from animals to humans and then from person to person through contact with infected bodily fluids or contaminated surfaces, leading to large and dangerous outbreaks.

What is the WHO Emergency Use Listing (EUL)?

The WHO Emergency Use Listing (EUL) is a procedure designed to accelerate access to essential health products, such as diagnostics, vaccines, and treatments, during public health emergencies. It assesses the quality, safety, and performance of these products based on available evidence, ensuring they meet minimum international standards and address the needs of low- and middle-income countries, thereby facilitating informed procurement and rapid deployment.

How will this new diagnostic test impact the current Ebola Bundibugyo outbreak?

The new EUL-approved molecular diagnostic test will significantly enhance the response to the current Ebola Bundibugyo outbreak by enabling rapid and accurate confirmation of infections. This early detection is crucial for timely patient isolation, appropriate clinical care, improved disease surveillance, and breaking chains of transmission. It also supports national and international efforts to procure and deploy trusted diagnostic tools more effectively in affected regions like the Democratic Republic of Congo and Uganda.